Sanofi backed its full-year earnings steerage after it reported first-quarter revenue forward of consensus, with gross sales progress pushed by continued energy in anti-inflammatory drug Dupixent and its new drug launches.
Sanofi backed its full-year earnings steerage after it reported first-quarter revenue forward of consensus, with gross sales progress pushed by continued energy in anti-inflammatory drug Dupixent and its new drug launches.
